These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 6378045

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Comparison of intravenous lorcainide with lidocaine for acute therapy of complex ventricular arrhythmias: results of a randomized study with crossover option.
    Anderson JL, Anastasiou-Nana M, Lutz JR, Writer SL.
    J Am Coll Cardiol; 1985 Feb; 5(2 Pt 1):333-41. PubMed ID: 3881497
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of lorcainide, a new anti-arrhythmic agent.
    Lloyd EA, Workman LJ, Commerford PJ, Mabin TA.
    S Afr Med J; 1981 Dec 12; 60(24):929-31. PubMed ID: 7302777
    [Abstract] [Full Text] [Related]

  • 6. Acute effects of antiarrhythmic drugs on stable ventricular premature beats. Controlled comparison of lorcainide and lidocaine.
    Schmidt G, Klein G, Wirtzfeld A.
    Eur J Clin Pharmacol; 1985 Dec 12; 27(6):633-6. PubMed ID: 2580712
    [Abstract] [Full Text] [Related]

  • 7. Intravenous lorcainide for symptomatic ventricular tachyarrhythmias: comparison with lidocaine and oral lorcainide.
    Hohnloser SH, Podrid PJ, Lown B.
    Am Heart J; 1988 Apr 12; 115(4):824-30. PubMed ID: 3354411
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Hemodynamic repercussions and clinical tolerance of 6 class I anti-arrhythmia agents in acute myocardial infarction].
    Bernard R, Renard M, Shita A, de Hemptinne J, Gillet JM, Lewinson H, Liebens I, Waterschoot P.
    Ann Cardiol Angeiol (Paris); 1986 Apr 12; 35(4):195-8. PubMed ID: 3090925
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Lorcainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.
    Eiriksson Ce, Brogden RN.
    Drugs; 1984 Apr 12; 27(4):279-300. PubMed ID: 6373222
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy and tolerance of intravenous lorcainide in patients with normal and impaired intraventricular conduction.
    Stroobandt R, Kesteloot H.
    Acta Cardiol; 1985 Apr 12; 40(6):637-48. PubMed ID: 3879420
    [Abstract] [Full Text] [Related]

  • 20. [Effects of lorcainide, a new antiarrhythmic agent, on experimental cardiac arrhythmias].
    Fukuda H, Goto M, Kondo M, Uchigasaki T, Sekino Y.
    Nihon Yakurigaku Zasshi; 1983 Feb 12; 81(2):115-26. PubMed ID: 6852683
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.